Company news

Ironwood Pharmaceuticals, Inc. news in 2021

Ironwood Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

November 30, 2021

Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update

November 3, 2021

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

November 3, 2021

More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021

October 24, 2021

Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call

October 20, 2021

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

September 1, 2021

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

August 25, 2021

Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance

August 4, 2021

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

August 2, 2021

Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call

July 21, 2021

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 15, 2021

Ironwood Pharmaceuticals Announces Leadership Updates

June 6, 2021

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength

May 25, 2021

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)

May 23, 2021

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021

May 16, 2021

Ironwood Pharmaceuticals Reports First Quarter 2021 Results

May 5, 2021

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

May 5, 2021

Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call

April 21, 2021

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance

February 16, 2021

Ironwood Pharmaceuticals Announces CEO Transition

February 7, 2021

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call

February 2, 2021

Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Calls in 2021

Decks in 2021